Citius Pharmaceuticals (CTXR) Expected to Announce Earnings on Wednesday

Citius Pharmaceuticals (NASDAQ:CTXR) is anticipated to post its Q2 2026 results before the market opens on Wednesday, May 13th. Analysts expect Citius Pharmaceuticals to post earnings of $0.3885 per share and revenue of $18.79 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, May 19, 2026 at 4:00 PM ET.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its earnings results on Friday, February 13th. The company reported ($0.38) earnings per share (EPS) for the quarter.

Citius Pharmaceuticals Stock Performance

Shares of NASDAQ:CTXR opened at $0.64 on Tuesday. Citius Pharmaceuticals has a 1 year low of $0.57 and a 1 year high of $2.48. The stock has a market capitalization of $14.29 million, a P/E ratio of -0.26 and a beta of 1.05. The stock has a 50-day simple moving average of $0.79 and a 200-day simple moving average of $0.94.

Hedge Funds Weigh In On Citius Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in Citius Pharmaceuticals in the 2nd quarter worth approximately $32,000. NewEdge Advisors LLC purchased a new position in Citius Pharmaceuticals in the 2nd quarter worth approximately $40,000. Asset Advisory Group Inc. purchased a new position in Citius Pharmaceuticals in the 4th quarter worth approximately $46,000. Finally, Heights Capital Management Inc. purchased a new position in Citius Pharmaceuticals in the 4th quarter worth approximately $622,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Friday, March 27th. D. Boral Capital restated a “buy” rating and issued a $6.00 price target on shares of Citius Pharmaceuticals in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.00.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.